Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases
Binhua Zou(Southern Medical University), Xiaojuan Li(Guilin Medical University), Ziye Chen(Southern Medical University), Wende Deng(Southern Medical University), Yan Chen(Sun Yat-sen University), Lihong Li(Southern Medical University), Weili He(Harvard University), Jiehuang Zheng(Guangdong Pharmaceutical University), Qinghe Liang(Southern Medical University)
Cited by 1
Related Papers
A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1995|339
Oral Hydrogel Microbeads-Mediated In Situ Synthesis of Selenoproteins for Regulating Intestinal Immunity and Microbiota
|Journal of the American Chemical Society|2023|177
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy
|Acta Pharmaceutica Sinica B|2021|158
Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer
|Nano Research|2020|145
Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway
|Acta Pharmacologica Sinica|2019|120